Follow
Antonis Kattamis
Antonis Kattamis
Verified email at med.uoa.gr
Title
Cited by
Cited by
Year
CRISPR-Cas9 gene editing for sickle cell disease and ‚-thalassemia
H Frangoul, D Altshuler, MD Cappellini, YS Chen, J Domm, BK Eustace, ...
New England Journal of Medicine 384 (3), 252-260, 2021
13262021
A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with ‚-thalassemia
MD Cappellini, A Cohen, A Piga, M Bejaoui, S Perrotta, L Agaoglu, ...
Blood 107 (9), 3455-3462, 2006
9382006
Prevalence of thromboembolic events among 8,860 patients with thalassaemia major and intermedia in the Mediterranean area and Iran
A Taher, H IsmaĘeel, G Mehio, D Bignamini, A Kattamis, EA Rachmilewitz, ...
Thrombosis and haemostasis 96 (10), 488-491, 2006
4032006
Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias
MD Cappellini, J Porter, A El-Beshlawy, CK Li, JF Seymour, M Elalfy, ...
haematologica 95 (4), 557, 2010
3512010
A phase 3 trial of luspatercept in patients with transfusion-dependent ‚-thalassemia
MD Cappellini, V Viprakasit, AT Taher, P Georgiev, KHM Kuo, T Coates, ...
New England Journal of Medicine 382 (13), 1219-1231, 2020
2592020
Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up
MD Cappellini, M Bejaoui, L Agaoglu, D Canatan, M Capra, A Cohen, ...
Blood, The Journal of the American Society of Hematology 118 (4), 884-893, 2011
2552011
Changing patterns in the epidemiology of ‚‐thalassemia
A Kattamis, GL Forni, Y Aydinok, V Viprakasit
European Journal of Haematology 105 (6), 692-703, 2020
2372020
Efficacy of deferasirox in reducing and preventing cardiac iron overload in ‚-thalassemia
DJ Pennell, JB Porter, MD Cappellini, A El-Beshlawy, LL Chan, Y Aydinok, ...
Blood, The Journal of the American Society of Hematology 115 (12), 2364-2371, 2010
2372010
The effects of erythropoetic activity and iron burden on hepcidin expression in patients with thalassemia major
A Kattamis, I Papassotiriou, D Palaiologou, F Apostolakou, A Galani, ...
haematologica 91 (6), 809-812, 2006
1972006
Recommendations regarding splenectomy in hereditary hemolytic anemias
A Iolascon, I Andolfo, W Barcellini, F Corcione, L Garçon, L De Franceschi, ...
haematologica 102 (8), 1304, 2017
1962017
Frameshift mutation in p53 regulator RPL26 is associated with multiple physical abnormalities and a specific pre‐ribosomal RNA processing defect in diamond†…
HT Gazda, M Preti, MR Sheen, MF O'Donohue, A Vlachos, SM Davies, ...
Human mutation 33 (7), 1037-1044, 2012
1902012
Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study
AT Taher, J Porter, V Viprakasit, A Kattamis, S Chuncharunee, ...
Blood, The Journal of the American Society of Hematology 120 (5), 970-977, 2012
1732012
Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with ‚-thalassemia major
DJ Pennell, JB Porter, MD Cappellini, LL Chan, A El-Beshlawy, Y Aydinok, ...
haematologica 97 (6), 842, 2012
1582012
Twenty-one additional cases of familial renal glucosuria: absence of genetic heterogeneity, high prevalence of private mutations and further evidence of volume depletion
J Calado, Y Sznajer, D Metzger, A Rita, MC Hogan, A Kattamis, M Scharf, ...
Nephrology Dialysis Transplantation 23 (12), 3874-3879, 2008
1482008
The pediatric precision oncology INFORM registry: clinical outcome and benefit for patients with very high-evidence targets
CM Van Tilburg, E Pfaff, KW Pajtler, KPS Langenberg, P Fiesel, BC Jones, ...
Cancer discovery 11 (11), 2764-2779, 2021
1392021
Iron chelation treatment with combined therapy with deferiprone and deferioxamine: a 12-month trial
A Kattamis, V Ladis, H Berdousi, NL Kelekis, E Alexopoulou, ...
Blood Cells, Molecules, and Diseases 36 (1), 21-25, 2006
1282006
Global characteristics and outcomes of SARS-CoV-2 infection in children and adolescents with cancer (GRCCC): a cohort study
S Mukkada, N Bhakta, GL Chantada, Y Chen, Y Vedaraju, L Faughnan, ...
The Lancet Oncology 22 (10), 1416-1426, 2021
1192021
Thalassaemia
A Kattamis, JL Kwiatkowski, Y Aydinok
The lancet 399 (10343), 2310-2324, 2022
1172022
R2 relaxometry with MRI for the quantification of tissue iron overload in ‚‐thalassemic patients
E Alexopoulou, F Stripeli, P Baras, I Seimenis, A Kattamis, V Ladis, ...
Journal of Magnetic Resonance Imaging: An Official Journal of the†…, 2006
1142006
Assessment of iron distribution between liver, spleen, pancreas, bone marrow, and myocardium by means of R2 relaxometry with MRI in patients with ‚‐thalassemia major
O Papakonstantinou, E Alexopoulou, N Economopoulos, O Benekos, ...
Journal of Magnetic Resonance Imaging: An Official Journal of the†…, 2009
1132009
The system can't perform the operation now. Try again later.
Articles 1–20